Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eurofins Scientific SE's gross profit for the
six
months ended in Dec. 2025 was $4,314 Mil. Eurofins Scientific SE's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was $8,480 Mil.
Eurofins Scientific SE (OTCPK:ERFSF) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Eurofins Scientific SE had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Eurofins Scientific SE Gross Profit Related Terms
Eurofins Scientific SE Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Gross Profit vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Gross Profit distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $8,480 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Eurofins Scientific SE (ERFSF) has a Gross Profit of $8,480 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Eurofins Scientific SE and its competitors.
Is Eurofins Scientific SE's Gross Profit too high?
Eurofins Scientific SE's current Gross Profit is $8,480 Mil. Overall, Eurofins Scientific SE has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Gross Profit compare to TMO and DHR?
Eurofins Scientific SE's Gross Profit of $8,480 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Diagnostics & Research company?
A good Gross Profit depends on the Medical Diagnostics & Research industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Eurofins Scientific SE and its competitors. Eurofins Scientific SE's current Gross Profit is $8,480 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $78.19, compared to a current price of $78.73 — trading 0.7% above its estimated fair value. The current Gross Profit is $8,480 Mil. Eurofins Scientific SE's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current Gross Profit is $8,480 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $78.73 is trading 0.7% above its estimated GF Value™ of $78.19.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
Gross Profit: $8,480 Mil
GF Value™: $78.19 vs. price of $78.73 (0.7% above fair value)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
76GF Score
Get the complete analysis for ERFSF
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
